전이성 신세포암에서 Everolimus 사용 후 유발된 간질성 폐렴 1예
Everolimus-Induced Interstitial Pneumonitis in a Patient with Metastatic Renal Cell Carcinoma: a Case Report
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Everolimus는 전이성 투명세포형 신세포암의 치료제로 쓰인다. 문헌에는 everolimus 사용 후 간질성 폐렴이 발생할 수 있는 것으로 되어 있으나, 국내의 보고는 없었다. 저자들은 전이성 신세포암에서 everolimus 투여한 후 발생한 간질성 폐렴 1예를 경험하였기에 문헌고찰과 함께 보고하는 바이다.
Abstract
Everolimus, an inhibitor of the mammalian target of rapamycin, is an active agent against metastatic renal cell carcinoma. Treatment with everolimus prolongs progression-free survival in patients with clear cell-type renal cell carcinoma that has progressed on vascular endothelial growth factor receptor tyrosine kinase inhibitors, such as sunitinib and/or sorafenib. Everolimus-induced interstitial pneumonitis is not rare and is sometimes fatal. Due to the potential for pulmonary toxicity due to everolimus, it is recommended that pulmonary complications be periodically evaluated. We report a case of everolimus-associated interstitial pneumonitis in a patient with metastatic renal cell carcinoma. (Korean J Med 2012;83:520-524)
참고문헌 (10)
- Shahani R, "Safety and clinical efficacy of everolimus in the treatment of advanced renal cell carcinoma (RCC)", Drug Healthc Patient Saf, 2, pp.85~91 (2010)
- Voss MH, "mTOR inhibitors in advanced renal cell carcinoma", Hematol Oncol Clin North Am, 25, pp.835~852 (2011)
- Motzer RJ, "Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors", Cancer, 116, pp.4256~4265 (2010)
- White DA, "Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma", Am J Respir Crit Care Med, 182, pp.396~403 (2010)
- Akata K, "Two cases of everolimus-associated interstitial pneumonia in patients with renal cell carcinoma", Intern Med, 50, pp.3013~3017 (2011)
- Yao M, "VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma", J Natl Cancer Inst, 94, pp.1569~1575 (2002)
- Kondo K, "Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth", PLoS Biol, 1, pp.83~ (2003)
- Coppin C., "Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and", or sorafenib, 2010, pp.4, 91~101
- Vahid B, "Pulmonary complications of novel antineoplastic agents for solid tumors", Chest, 133, pp.528~538 (2008)
- Camus P, "Interstitial lung disease associated with drug therapy", Br J Cancer, 91(Suppl 2), pp.18~23 (2004)